Short Interest in Unity Biotechnology, Inc. (NASDAQ:UBX) Declines By 35.5%

Unity Biotechnology, Inc. (NASDAQ:UBXGet Rating) was the target of a large decline in short interest in May. As of May 15th, there was short interest totalling 448,000 shares, a decline of 35.5% from the April 30th total of 694,600 shares. Based on an average trading volume of 534,800 shares, the days-to-cover ratio is currently 0.8 days. Currently, 0.9% of the shares of the stock are short sold.

Several large investors have recently bought and sold shares of UBX. Acadian Asset Management LLC boosted its holdings in shares of Unity Biotechnology by 39.8% during the first quarter. Acadian Asset Management LLC now owns 389,893 shares of the company’s stock worth $435,000 after purchasing an additional 111,097 shares during the last quarter. GSA Capital Partners LLP grew its holdings in Unity Biotechnology by 4.0% in the 1st quarter. GSA Capital Partners LLP now owns 724,202 shares of the company’s stock valued at $811,000 after buying an additional 28,087 shares during the period. Walleye Capital LLC boosted its position in shares of Unity Biotechnology by 331.2% in the fourth quarter. Walleye Capital LLC now owns 54,365 shares of the company’s stock worth $79,000 after acquiring an additional 41,758 shares during the last quarter. Goldman Sachs Group Inc. grew its holdings in Unity Biotechnology by 116.3% in the fourth quarter. Goldman Sachs Group Inc. now owns 90,164 shares of the company’s stock valued at $132,000 after purchasing an additional 48,483 shares during the period. Finally, Virtu Financial LLC acquired a new position in Unity Biotechnology during the fourth quarter worth approximately $78,000. 21.22% of the stock is owned by institutional investors and hedge funds.

Several equities analysts recently issued reports on UBX shares. Citigroup reduced their price objective on Unity Biotechnology from $6.00 to $5.00 and set a “na” rating for the company in a report on Tuesday, May 17th. Zacks Investment Research downgraded shares of Unity Biotechnology from a “buy” rating to a “hold” rating in a report on Wednesday, May 18th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat, Unity Biotechnology presently has an average rating of “Buy” and an average price target of $5.61.

UBX opened at $0.83 on Friday. The firm has a market cap of $57.21 million, a P/E ratio of -0.77 and a beta of 0.39. The business’s fifty day simple moving average is $0.98 and its 200 day simple moving average is $1.29. Unity Biotechnology has a 52 week low of $0.70 and a 52 week high of $5.09.

Unity Biotechnology (NASDAQ:UBXGet Rating) last released its earnings results on Tuesday, May 10th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.02). On average, research analysts forecast that Unity Biotechnology will post -1.1 earnings per share for the current fiscal year.

About Unity Biotechnology (Get Rating)

Unity Biotechnology, Inc, a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy.

Featured Articles

Receive News & Ratings for Unity Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unity Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.